Literature DB >> 697229

Hepatitis from intravenous high-dose oxacillin therapy: findings in an adult inpatient population.

I M Onorato, J L Axelrod.   

Abstract

A retrospective review of all patients who received oxacillin intravenously in doses greater than 6 g/day was done. Eight patients in whom oxacillin-associated hepatitis developed were found and compared with a control group of 46 patients who had received high-dose oxacillin and in whom oxacillin-associated hepatitis did not develop. The latent period to development of typical symptoms of hepatitis varied from 2 to 21 days. Laboratory abnormalities were compatible with anicteric hepatitis and reverted to normal after withdrawal of the drug. Oxacillin hepatitis most like represents a hypersensitivity reaction. We recommend that routine liver chemistries be done regularly in all patients receiving high-dose intravenous oxacillin.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 697229     DOI: 10.7326/0003-4819-89-4-497

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  9 in total

Review 1.  Beta-lactam antibiotics inhibit human in vitro granulopoiesis and proliferation of some other cell types.

Authors:  K A Neftel; M R Müller; U Widmer; A W Hügin
Journal:  Cell Biol Toxicol       Date:  1986-12       Impact factor: 6.691

Review 2.  Effects of beta-lactam antibiotics on proliferating eucaryotic cells.

Authors:  K A Neftel; U Hübscher
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

Review 3.  Flucloxacillin associated cholestatic hepatitis. An Australian and Swedish epidemic?

Authors:  B M Devereaux; D H Crawford; P Purcell; L W Powell; H P Roeser
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

4.  Side effects of cloxacillin in infants and children.

Authors:  M A St John; C G Prober
Journal:  Can Med Assoc J       Date:  1981-09-01       Impact factor: 8.262

Review 5.  Nafcillin-associated hepatotoxicity. Report of a case and review of the literature.

Authors:  M E Presti; C G Janney; B A Neuschwander-Tetri
Journal:  Dig Dis Sci       Date:  1996-01       Impact factor: 3.199

6.  Cholestatic jaundice caused by cloxacillin: macrophage inhibition factor test in preventing rechallenge with hepatotoxic drugs.

Authors:  R Enat; S Pollack; Y Ben-Arieh; E Livni; D Barzilai
Journal:  Br Med J       Date:  1980-04-05

7.  Antimicrobial-related severe adverse events during treatment of bone and joint infection due to methicillin-susceptible Staphylococcus aureus.

Authors:  Florent Valour; Judith Karsenty; Anissa Bouaziz; Florence Ader; Michel Tod; Sébastien Lustig; Frédéric Laurent; René Ecochard; Christian Chidiac; Tristan Ferry
Journal:  Antimicrob Agents Chemother       Date:  2013-11-18       Impact factor: 5.191

8.  Systematic overdosing of oxa- and cloxacillin in severe infections treated in ICU: risk factors and side effects.

Authors:  Mathilde Neuville; Najoua El-Helali; Eric Magalhaes; Aguila Radjou; Roland Smonig; Jean-François Soubirou; Guillaume Voiriot; Alban Le Monnier; Stéphane Ruckly; Lila Bouadma; Romain Sonneville; Jean-François Timsit; Bruno Mourvillier
Journal:  Ann Intensive Care       Date:  2017-03-22       Impact factor: 6.925

9.  Nafcillin-Induced Allergic Eosinophilic Cholestatic Hepatitis.

Authors:  Mark V Guido; Warit Jithpratuck; Graham E Parks; Guha Krishnaswamy
Journal:  Gastroenterology Res       Date:  2017-06-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.